William Roth, MD, assistant professor of neurology at the University of Chicago, discusses the role of the gut microbiome in stroke risk and recovery and emerging strategies to modify it in the acute and preventive settings.
Three randomized trials pooled in a new systematic review found that thrombectomy did not improve 90-day functional outcomes after medium or distal vessel occlusion stroke, while increasing bleeding risk.
Brian Lin, PhD, senior director of research at the Muscular Dystrophy Association (MDA), discussed the sessions he is most excited about at the 2027 MDA Clinical and Scientific Conference.
A real-world registry found that large infarct core size does not independently predict worse functional or safety outcomes after thrombectomy, compared with moderate-core infarcts.
Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, discussed how the 2027 MDA Clinical and Scientific Conference agenda reflects key themes in neuromuscular medicine.
Odinachi Oguh, MD, movement disorder specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health, shares clinical perspectives on biomarkers, aging, non-motor symptoms, and prodromal disease from the 2026 MDS Congress.
A new phase 2b trial, SPINOZA, will test whether obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, slows Alzheimer disease biomarker progression in APOE-stratified, cognitively unimpaired adults.